EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Hemoperfusion Therapy’s Efficiency in Reducing Serum IL-6 Levels and Disease Severity in COVID-19 Patients

Mohammad Bakhshivand, Farid Ghorbaninezhad, Somaye Mirzayi, Nima Hemmat, Khalil Ansarin, Mohammad Reza Ardalan, Ali Taghizadieh, Maseoud Nazemiyeh, Mahdi Jafarlou, Farid Rashidi, Armin Sadeghi, Arsalan Yazdchi, Saeid Safiri, Haleh Mikaeili

ImmunoAnalysis · 2022

DOI: 10.34172/ia.2022.10 ↗
AbstractBibliografische Angaben

Abstract

Background: Interleukin (IL)-6, one of the inflammatory mediators involved in severe cases of coronavirus disease-19 (COVID-19), has been implicated in the pathogenesis of this disease. Extracorporeal blood purification has been suggested as one of the therapeutic strategies for COVID-19 patients, due to its favorable effect on the removal of inflammatory cytokines. Here, we investigated the impact of hemoperfusion (HP), a type of extracorporeal blood purification, in serum IL-6 levels and disease severity in COVID-19 patients. Methods: 35 patients with severe COVID-19 were enrolled in this study at the Imam-Reza Hospital, Tabriz University of Medical Sciences, between April 2020 and June 2020. The HA330 disposable HP cartridge was utilized (Jafron Biomedical Company, China). After a hemodialysis catheter was placed, patients underwent HP for at least three days in a row. Results: Our results indicated that COVID-19 patients’ serum levels of IL-6 significantly diminished following HP (P value≤0.001). Furthermore, a decrease in IL-6 levels following HP demonstrated the effectiveness of this approach (area under the curve [AUC]=0.7102 and P=0.0025). Conclusion: Taken together, our findings suggest HP as a promising therapeutic option in COVID-19. However, a detailed evaluation of HP’s efficacy is required in large prospective multicenter trials.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →